Naveena Singh

Naveena Singh

Auto-generated profile, based on publicly available information

Naveena Singh

Department of Cellular Pathology, Barts Health NHS Trust, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2019 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
NSNaveena Singh
Naveena Singh
APAnna M. Piskorz
Anna M. Piskorz
TBTjalling Bosse
Tjalling Bosse
MJMercedes Jimenez‐Linan
Mercedes Jimenez‐Linan
BRBrian Rous
Brian Rous
MKMartin Köbel
Martin Köbel

25 June 2022 in Laboratory Investigation
Verified
Journal Article
Open access
LVLisa Vermij
Lisa Vermij
ALAlicia Léon-Castillo
Alicia Léon-Castillo
NSNaveena Singh
Naveena Singh
MPMelanie E. Powell
Melanie E. Powell
RERichard J. Edmondson
Richard J. Edmondson
HMH. MacKay
H. MacKay
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation of routinely performed p53 IHC has therefore become of paramount importance. We aimed to comprehensively investigate abnormal p53 IHC patterns and their relation to clinicopathological and molecular features. Tumor material of 411 molecularly classified high-risk EC from consenting patients from the PORTEC-3 clinical trial were collected. p53 IHC was successful in 408 EC and was considered abnormal when the tumor showed a mutant expression pattern (including subclonal): overexpression, null or cytoplasmic. The presence of pathogenic mutations was determined by next generation sequencing (NGS). Abnormal p53 expression was observed in 131/408 (32%) tumors. The most common abnormal p53 IHC pattern was overexpression (n = 89, 68%), followed by null (n = 12, 9%) and cytoplasmic (n = 3, 2%). Subclonal abnormal p53 staining was observed in 27 cases (21%), which was frequently but not exclusively, associated with POLE mutations and/or MMRd (n = 22/27; p < 0.001). Agreement between p53 IHC and TP53 NGS was observed in 90.7%, resulting in a sensitivity and specificity of 83.6% and 94.3%, respectively. Excluding POLEmut and MMRd EC, as per the WHO-endorsed algorithm, increased the accuracy to 94.5% with sensitivity and specificity of 95.0% and 94.1%, respectively. Our data shows that awareness of the abnormal p53 IHC patterns are prerequisites for correct EC molecular classification. Subclonal abnormal p53 expression is a strong indicator for POLEmut and/or MMRd EC. No significant differences in clinical outcomes were observed among the abnormal p53 IHC patterns. Our data support use of the WHO-endorsed algorithm and combining the different abnormal p53 IHC patterns into one diagnostic entity (p53abn EC).

1 January 2019 in International Journal of Gynecological Pathology
Verified
Journal Article
Open access
NSNaveena Singh
Naveena Singh
LHLynn Hirschowitz
Lynn Hirschowitz
RZRichard Zaino
Richard Zaino
IAIsabel Alvarado-Cabrero
Isabel Alvarado-Cabrero
MDMaire A. Duggan
Maire A. Duggan
EOEsther Oliva
Esther Oliva
Although endometrial carcinoma (EC) is generally considered to have a good prognosis, over 20% of women with EC die of their disease, with a projected increase in both incidence and mortality over the next few decades. The aim of accurate prognostication is to ensure that patients receive optimal treatment and are neither overtreated nor undertreated, thereby improving patient outcomes overall. Patients with EC can be categorized into prognostic risk groups based on clinicopathologic findings. Other than tumor type and grade, groupings and recommended management algorithms may take into account age, body mass index, stage, and presence of lymphovascular space invasion. The molecular classification of EC that has emerged from the Cancer Genome Atlas (TCGA) study provides additional, potentially superior, prognostic information to traditional histologic typing and grading. This classifier does not, however, replace clinicopathologic risk assessment based on parameters other than histotype and grade. It is envisaged that molecular and clinicopathologic prognostic grouping systems will work better together than either alone. Thus, while tumor typing and grading may be superseded by a classification based on underlying genomic abnormalities, accurate assessment of other pathologic parameters will continue to be key to patient management. These include those factors related to staging, such as depth of myometrial invasion, cervical, vaginal, serosal surface, adnexal and parametrial invasion, and those independent of stage such as lymphovascular space invasion. Other prognostic parameters will also be discussed. These recommendations were developed from the International Society of Gynecological Pathologists Endometrial Carcinoma project.

5 September 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
HFHossein Farahani
Hossein Farahani
JBJeffrey Boschman
Jeffrey Boschman
DFDavid Farnell
David Farnell
ADAmirali Darbandsari
Amirali Darbandsari
AZAllen Zhang
Allen Zhang
ABAli Bashashati
Ali Bashashati

17 December 2019 in Histopathology
Verified
Journal Article
Closed access
PDF file
NSNaveena Singh
Naveena Singh
CGC Blake Gilks
C Blake Gilks

18 July 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
NSNaveena Singh
Naveena Singh
GMGlenn McCluggage
Glenn McCluggage
CGC Blake Gilks
C Blake Gilks